Company Overview and News
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
We’ve never been fans of direct commodities investments and have been warning about the lack of risk adjusted returns that commodities funds offer investors for years. In previous articles, we focused on the structural issues with commodities markets and commodities funds that make them unworthy of inclusion in investors’ portfolios. In this article, we want to focus on a different aspect of commodities funds that make them unattractive.
HAL RIO RIO BLT XOM APD PSX COP SHW RTPPF RTNTF VDE BHPBF VLO DWDP VALE PPG PX BHP RIO CVX DBC VAW BBL BHP PDBC SLB BHPLF AI
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGT
24 of 45 Basic Materials top yield 'WallStar' stocks were tagged "safer" for dividends because they showed positive annual-returns, and free cash-flow yields greater than their dividend yields 5/10/18.
OLN APD SXCP WLK CBT LYB RGORF GOLD RRS DWDP GOLD ACIIQ MRI.U ACI MERC LALWF ARCH
41 of 80 Dividend Champions (25 or more annual dividend hikes) were tagged 'safer' by showing positive annual returns, and free cash-flow yields greater than their dividend yields calculated 5/7/18.
APD O.PRF O MDP OPRF KMB NNN.PRD NNN.PRF NNN.PRE ERIE PEP JNJ CVX LEG MCD NNN ERIEB
DALLAS, May 10, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Alternet Systems, Inc. (USOTC:ALYI) today announced the shipping of its first pilot production motorcycles is ahead of schedule. The company recently launched an Electric Vehicle (EV) business called ReVolt Electric Motorbikes utilizing the company’s portfolio of patented lithium battery technologies developed by Air Products and Chemicals, Inc.
41 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 5/2/18.
LOW APD KMB PEP JNJ CINF CVX ITW DOV ABBV ABBV LEG MCD
"S&P 500® Dividend Aristocrats measure the performance S&P 500 companies that have increased dividends every year for the last 25 consecutive years."---us.spindices.com.
APD XOM WBA KMB NUE CTAS PEP JNJ CVX ABBV ED LEG ABBV
Document UNITED STATES
A few prominent chemical companies are scheduled to report their quarterly numbers on Apr 26. The chemical industry is riding high on an upturn in the world economy and continued strength across major end-use markets such as construction, automotive and electronics. Another positive for the industry is a recovery in demand in the energy space – a key chemical end-market that had been out of favor for a spell.
APD TWX MS.PRE MS.PRF MS.PRG MS.PRA TWC EMN.WS MS.PRI PX EMN MS.PRK MS POL
4h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
6h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to APD / Air Products & Chemicals, Inc. on message board site Silicon Investor.
|APDR - Apollo Drilling, Inc.|
as of ET